| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
SATA Protein Modifier does not have a biological target in the context of pharmacology. It is a chemical reagent used for protein modification in biochemical research. The compound contains an N-hydroxysuccinimide (NHS) ester group that reacts with primary amine groups on proteins (e.g., lysine residues) to form stable amide bonds. The S-acetylthioacetate moiety introduces a protected thiol group that can be deprotected by hydroxylamine to expose a free sulfhydryl for conjugation with maleimide or other thiol-reactive groups.
|
|---|---|
| ln Vitro |
In vitro, SATA Protein Modifier is used to modify proteins by introducing protected sulfhydryl groups. The NHS ester reacts with primary amines on proteins under mild conditions (pH 7-8), forming stable amide bonds. The acetyl-protected thiol can be deprotected using hydroxylamine to generate a free thiol group. The modified protein can then be conjugated to other molecules containing maleimide, iodoacetyl, or other thiol-reactive groups. SATA is widely used in the preparation of antibody-drug conjugates and other bioconjugates.
|
| ln Vivo |
SATA Protein Modifier is not a pharmacologically active compound and is not evaluated for in vivo activity. Its applications are limited to in vitro protein modification in biochemical research. The compound is used to prepare modified proteins for various applications, including the development of antibody-drug conjugates, protein labeling, and crosslinking studies. No in vivo efficacy studies are conducted for SATA because it is not intended to treat any disease.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to SATA Protein Modifier because it is a chemical reagent rather than a drug candidate. However, the compound may be characterized by physicochemical methods such as HPLC for purity analysis, melting point determination, and solubility testing. Its reactivity with primary amines can be assessed using model compounds or protein substrates to confirm its functionality as a protein modification reagent.
|
| Cell Assay |
In vitro cellular assays are not typically performed for SATA Protein Modifier because it is a reagent rather than a drug candidate. When used in cell culture, the compound may be tested for cytotoxicity to ensure it does not adversely affect cell viability at concentrations used in protein modification protocols. Standard cytotoxicity assays such as MTT or LDH release can be employed to assess cell viability following exposure to SATA. However, these are not routine tests for this compound, as it is primarily used as a biochemical reagent.
|
| Animal Protocol |
SATA Protein Modifier is not a pharmacologically active compound and is not evaluated for in vivo therapeutic efficacy. No in vivo animal experiments are conducted for SATA because it is not intended for therapeutic use. The compound is used exclusively in biochemical research for protein modification, and its applications are limited to in vitro studies. Safety and toxicity studies are not typically performed for this reagent in the context of drug development.
|
| ADME/Pharmacokinetics |
SATA Protein Modifier has a molecular weight of 231.23 g/mol and a molecular formula of C8H9NO5S. The compound is soluble in DMSO at approximately 100 mg/mL (~432.47 mM). It is stable as a powder at -20°C for up to 3 years and in solution at -80°C for up to 6 months. The compound is not stable in solution and should be used freshly prepared for optimal results. It should be stored in a sealed, protected environment (e.g., under nitrogen) to avoid exposure to moisture.
|
| Toxicity/Toxicokinetics |
The toxicological profile of SATA Protein Modifier has not been extensively characterized because it is a research reagent rather than a drug candidate. The compound may cause irritation upon contact with skin or mucous membranes. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. Comprehensive toxicology studies are not necessary for this reagent, as it is not intended for human use.
|
| References |
|
| Additional Infomation |
SATA Protein Modifier is a biochemical reagent used for protein modification in research applications. It is also known as N-Succinimidyl S-Acetylthioacetate. The compound contains an NHS ester that reacts with primary amines on proteins to introduce protected sulfhydryl groups, which can later be deprotected and conjugated to thiol-reactive molecules. SATA is widely used in the preparation of antibody-drug conjugates, protein labeling, and crosslinking studies. It is not a drug and has no therapeutic indications.
|
| Molecular Formula |
C8H9NO5S
|
|---|---|
| Molecular Weight |
231.2258
|
| Exact Mass |
231.02
|
| CAS # |
76931-93-6
|
| Related CAS # |
76931-93-6;
|
| PubChem CID |
127532
|
| Appearance |
White to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
337.3±44.0 °C at 760 mmHg
|
| Melting Point |
84-89ºC
|
| Flash Point |
157.8±28.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.562
|
| LogP |
-1.16
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FLCQLSRLQIPNLM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H9NO5S/c1-5(10)15-4-8(13)14-9-6(11)2-3-7(9)12/h2-4H2,1H3
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~432.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3247 mL | 21.6235 mL | 43.2470 mL | |
| 5 mM | 0.8649 mL | 4.3247 mL | 8.6494 mL | |
| 10 mM | 0.4325 mL | 2.1623 mL | 4.3247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA